We report the first demonstration, to the best of our knowledge, of visible mode-locked fiber laser using frequency-shifted feedback (FSF) with a visible α-BaTeMoO (α-BTM) crystal acousto-optic modulator (AOM). First, an α-BTM crystal is used as the visible high-quality AOM with a high diffraction efficiency of 85, a fast rise/fall time of 79/98 ns, and a low insertion loss of 0.2 dB at 635 nm.
View Article and Find Full Text PDFBackground: Extraintestinal metastasis is the main therapeutic challenge for colorectal cancer, the third most common cancer worldwide. Various components of the tumor microenvironment, especially cancer-associated fibroblasts (CAFs), play important roles in tumor metastasis. NAMPT is often overexpressed in tumor tissues and is associated with poorer prognosis.
View Article and Find Full Text PDFColorectal cancer (CRC) is a cancer with a high morbidity and mortality worldwide. Hence, developing new therapeutic drugs for CRC is very important. Moxidectin (MOX) has shown good anti-glioblastoma effect both in vitro and in vivo.
View Article and Find Full Text PDFColorectal cancer (CRC) is one of the most common malignancies worldwide. Metastasis is a major cause of CRC recurrence and mortality. Several antibiotic drugs have been reported to exert potential anticancer activities, however, whether and how the tetracycline antibiotic minocycline exhibit tumor suppressive effect on CRC remains unknown.
View Article and Find Full Text PDFBackground: Inflammation is one of a main reason for colon cancer progression and poor prognosis. The high-mobility group box-1 (HMGB1) and glutathione peroxidase 4 (GPX4) are responsible for inflammation, but the relationship between HMGB1 and GPX4 remains unknown about inflammation in colon cancer.
Methods: RT-qPCR was carried out to investigate the expression of IL1β, IL6 and TNFα in colon cancer cells stimulated with LPS or siHMGB1.
Objectives: Alzheimer's disease (AD) is one of the most prevalent brain diseases among the elderly, majority of which is caused by abnormal deposition of amyloid beta-peptide (Aβ). Galantamine, currently the first-line drug in treatment of AD, has been shown to diminish Aβ-induced neurotoxicity and exert favourable neuroprotective effects, but the detail mechanisms remain unclear.
Materials And Methods: Effects of galantamine on Aβ-induced cytotoxicity were checked by MTT, clone formation and apoptosis assays.